Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with psychostimulants, and numerous convenient, once-daily, long-acting psychostimulants in a variety of distinct formulations are now available in the United States. However, the FDA classifies psychostimulants as controlled substances because of the potential for abuse. Although nonstimulant therapies have become key therapeutic alternatives, a lingering perception of their less-robust efficacy versus that of psychostimulants has enabled psychostimulants to maintain a strong presence in the treatment algorithm for pediatric ADHD.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric ADHD patients?
  • How have branded drugs (e.g., Shire’s Vyvanse) been integrated into the treatment algorithm?
  • What proportion of pediatric ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of pediatric ADHD patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
  • What are the product-level compliance and persistency rates among drug-treated pediatric patients with ADHD?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Eli Lilly, Janssen, Novartis, Pfizer, Shire

Key drugs: Atomoxetine (Strattera, generics), guanfacine ER (Intuniv, generics), methylphenidate ER (Concerta, generics), Quillichew ER, Ritalin LA, Vyvanse

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Attention-Deficit-Hyperactivity Disorder - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis
    • Treatment Algorithm CDA- Attention-Deficit/Hyperactivity Disorder-May 2018

Author(s): Niyati Khetarpal, Ph.D

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”